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Fig. 1. 
From the Pulmonary Artery: New Operative Technique." 
Use of native pulmonary artery to fashion a tube that 
would then allow connection of the left coronary artery to 
the aorta is an excellent option when direct implantation 
is not possible. 
We discovered a photograph in one of our slide collec- 
tions (J.A.W.) that depicted an operation proposed by Dr. 
Harris Shumacker at Indiana University in 1962, more 
than 30 years ago (Fig. 1). Although the infant died before 
the operation could be undertaken, it was performed in 
the autopsy room. 2 We believe this "old" technique 
should be in the congenital heart surgeons' armentarimn 
when faced with a patient in whom the left coronary artery 
cannot be directly reimplanted and some other technique 
is required to span the distance from the aorta to the 
ostium of the left coronary artery. 
John L. ?dyers, MD 
John A. Waldhausen, MD 
The Pennsylvania State University 
The Milton S. Hershey Medical Center 
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Topical effect of aprotinin on the surgical wound 
in cardiac surgery 
To the Editor: 
The best way to apply aprotinin is unknown in cardiac 
surgery, because the mechanism of aprotinin in preserving 
hemostasis remains under investigation, a' 2 We have been 
recommending the use of low-dose aprotinin (2 million 
KIU) in the pump prime, because we demonstrated that 
low-dose aprotinin is sufficient o preserve platelet glyco- 
protein Ib receptors 3 and ristocetin agglutination capacity 
of platelets 4 during cardiopulmonary b pass (CPB). These 
seem to be the main mechanisms of aprotinin in preserv- 
ing hemostasis. This efficacy and the sufficiency of low- 
dose aprotinin were reproduced by the ptatelet aggrega- 
tion model on the extracellular matrix. 5Another possible 
mechanism of aprotinin in preserving hemostasis i the 
preservation of fibrin hemostatic sealing by the inhibition 
of fibrinolysis, a However, the direct effect of fibrinolysis in 
impairing hemostasis remains unclear, 1because no clear 
evidence has been collected regarding how much the 
increase of fibrin-split products in the systemic irculation 
stands for the lysis of fibrin hemostatic sealing on the 
wound surface. 
Of great interest is a recent report of Tatar and 
associates, ~ who demonstrated the efficacy of aprotinin 
(1 million KIU) on hemostasis when used topically in the 
pericardial cavity before closure of the thorax cavity. This 
observation certainly suggests that the inhibition of fibri- 
nolysis on the closed thorax cavity stabilizes the fibrin 
hemostatic sealing on the wound surface, contributing to 
hemostasis. If aprotinin is applied topically, its effect 
seems olely based on antifibrinolysis. In a previous tudy, 
we 7 demonstrated enormous activation of fibrinolysis on 
the surgical wound by sampling blood from the thoracic 
cavity. This method might reveal the topical effect of 
4 0 0 Letters to the Editor 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1995 
Table I. Fibrin degradation products (ng/ml) 
Source of blood Placebo Aprotinin 
Systemic circulation 1,620 + 420 970 -+ 330* 
Surgical wound 38,200 + 9,300 17,900 -+ 6,800? 
The data are presented asmean +- standard deviation. 
*p < 0.05. 
Cp < 0.01. 
aprotinin on the wound surface, proving the hypothesis 
that a stable fibrin sealing of the wound prevents postop- 
erative bleeding. 
Therefore, we conducted a study in 12 patients under- 
going coronary m-tery bypass grafting randomly treated 
with placebo or low-dose aprotinin in the pump prime. 
The blood oozing from the surgical wound was collected 
in the pericardial cavity and sampled during creation of 
the distal coronary anastomoses. Blood samples from the 
systemic irculation were taken simultaneously for com- 
parison. An enormous increase of fibrin degradation 
products was observed in the blood of the surgical wound 
compared with systemic blood (p < 0.01) (Table I). Likely, 
the increased fibrin degradation products in the blood 
from the surgical wound represents the Iysis of the fibrin 
hemostatic sealing on the wound surface. Aprotinin re- 
duced fibrin degradation products in wound blood only by 
half (p < 0.01) (Table I). This result indicates that 
systemically applied low-dose aprotinin could reduce but 
not prevent lysis of hemostatic fibrin sealing on the wound 
surface during CPB. Moreover, after closure of the tho- 
racic cavity this fibrinolytic state could be even more 
intensified by the increased activity of tissue-plasminogen 
activator from the pericardiumfi Therefore the topical use 
of aprotinin before closure of the thoracic avity could be 
most effective in preserving fibrin hemostatic sealing on 
the wound surface. The scheme for low-dose aprotinin 
was designed to preserve platelet function during CPB 3 
but not to maintain the antifibrinolytic apacity after 
closure of the thoracic cavil),. Therefore use of topical 
aprotinin might be recommended in addition to tow-dose 
use in the pump prime to amplify the hemostatic capacity 
of aprotinin by two mechanisms: preserving platelet func- 
tion during CPB and preserving fibrin hemostatic sealing 
after closure of the thoracic cavity. 
N. Tabuchi, MD 
J. de Haan, PhD 
W. van Oeveren, PhD 
Thoraxcenter 
Blood Interaction Research 
University Hospital Groningen 
Groningen, The Netherlands 
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Invited letter concerning: Topical aprotinin 
To the Editor: 
The use of topical aprotinin as proposed by Tatar and 
associates 1 is based on an empiric observation and needs 
to be confirmed. The idea is interesting, but the mecha- 
nism is not clear. The data and insights presented by 
Tabuchi, de Haan, and van Oeveren 2 are very relevant 
and valuable. 
The association constant (Ki) of aprotinin and plasmin 
is 0.23 nmol/L, but it is only 30 nmol/L for kallikrein) The 
high-dose protocol (4 mg/kg load; 4 mg/kg in pump prime) 
produces blood concentrations during cardiopulmonary 
bypass (CPB) of approximately 175 to 275 KIU/ml; with 
the half-dose protocol, concentrations range from approx- 
imately 115 to 165 KIU/ml. 4 These concentrations e tab- 
lished before and during the operation are sufficient o 
completely inhibit plasmin and succeed in attenuating 
production of D-dimer, a marker of fibrinolysis. 5 In 
addition, systemic aprotinin protects the platelet glyco- 
protein Ib receptor, probably by preventing plasmin- 
induced infolding of the receptor into platelet subcannicu- 
lar canals as demonstrated by Cramer and associatesfi 
This makes the glycoprotein Ib receptor available to 
participate in the formation of the hemostatic plug to 
produce the decrease in postoperative bleeding times 
associated with systemic aprotinin. 7 Platelet activation is 
also suppressed by unknown mechanisms that may be 
related to suppression of neutrophil activation. 8 However, 
kallikrein, which accelerates the intrinsic coagulation 
pathway, is only partially inhibited by systemic aproti- 
nin,9, lo but this is sufficient o reduce thrombin formation 
during CPB. Because of the doses required, systemic 
aprotinin probably does not appreciably inhibit factor 
